GUD vs. WEED, OGI, ACB, CPH, CRON, TLRY, EXE, FRX, KSI, and VHI
Should you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Canopy Growth (WEED), Organigram (OGI), Aurora Cannabis (ACB), Cipher Pharmaceuticals (CPH), Cronos Group (CRON), Tilray Brands (TLRY), Extendicare (EXE), Fennec Pharmaceuticals (FRX), kneat.com (KSI), and Vitalhub (VHI). These companies are all part of the "medical" sector.
Knight Therapeutics (TSE:GUD) and Canopy Growth (TSE:WEED) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking.
Knight Therapeutics has higher earnings, but lower revenue than Canopy Growth. Knight Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Canopy Growth has a net margin of 0.00% compared to Knight Therapeutics' net margin of -5.13%. Knight Therapeutics' return on equity of -2.14% beat Canopy Growth's return on equity.
Knight Therapeutics presently has a consensus price target of C$6.58, suggesting a potential upside of 24.21%. Canopy Growth has a consensus price target of C$3.20, suggesting a potential downside of 72.56%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Knight Therapeutics is more favorable than Canopy Growth.
13.8% of Knight Therapeutics shares are held by institutional investors. Comparatively, 4.9% of Canopy Growth shares are held by institutional investors. 46.5% of Knight Therapeutics shares are held by company insiders. Comparatively, 19.0% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Knight Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.
Canopy Growth received 530 more outperform votes than Knight Therapeutics when rated by MarketBeat users. However, 75.34% of users gave Knight Therapeutics an outperform vote while only 62.44% of users gave Canopy Growth an outperform vote.
In the previous week, Knight Therapeutics had 3 more articles in the media than Canopy Growth. MarketBeat recorded 13 mentions for Knight Therapeutics and 10 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.86 beat Knight Therapeutics' score of 0.14 indicating that Canopy Growth is being referred to more favorably in the news media.
Summary
Knight Therapeutics beats Canopy Growth on 11 of the 18 factors compared between the two stocks.
Get Knight Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Knight Therapeutics Competitors List
Related Companies and Tools